Urocortin II (human) (trifluoroacetate salt)
目录号 : GC18231A neuropeptide hormone
Cas No.:398001-88-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I. Human urocortin II shares 34, 43, and 37-40% sequence homology with rat and human CRF, human urocortin , and human urocortin III. Urocortin II increases cell shortening and accelerates relaxation of rabbit ventricular myocytes in a time- and concentration-dependent manner. In vivo, urocortin reduces arterial blood pressure in normotensive and spontaneously hypertensive rats via peripheral CRF2 receptor agonism. It induces dose-dependent tachycardia and hypotension in rats when administered at doses of 3 and 30 pmol/kg. Urocortin (10 and 20 μg/kg) also reduces the visceral pain response to colorectal distension in conscious rats and delays gastric emptying in mice.
References:
[1]. Ad?o, R., Santos-Ribeiro, D., Rademaker, M.T., et al. Urocortin 2 in cardiovascular health and disease Drug Discov. Today 20(7), 906-914 (2015).
[2]. Gardiner, S.M., March, J.E., Kemp, P.A., et al. Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats J. Pharmacol. Exp. Ther. 312(1), 53-60 (2005).
[3]. Million, M., Wang, L., Wang, Y., et al. CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats Gut 55(2), 172-181 (2006).
Cas No. | 398001-88-2 | SDF | |
化学名 | N/A | ||
Canonical SMILES | N/A | ||
分子式 | C194H339N63O54S.XCF3COOH | 分子量 | 4450.2 |
溶解度 | Formic Acid: 1 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.2247 mL | 1.1235 mL | 2.2471 mL |
5 mM | 0.0449 mL | 0.2247 mL | 0.4494 mL |
10 mM | 0.0225 mL | 0.1124 mL | 0.2247 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。